Picture of Palisade Bio logo

PALI — Palisade Bio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Palisade Bio Inc expected to post a loss of $2.93 a share - Earnings Preview

* Palisade Bio Inc  PALI.OQ   PALI.O  is expected to show no
change in quarterly revenue when it reports  results on August 9
(estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Palisade Bio Inc is for
a loss
of $2.93 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Palisade
Bio Inc
is $33.75​, above​ its last closing price of $3.61. ​​​

This summary was machine generated August 7 at 15:19 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Palisade Bio

See all news